Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Sterling Capital Management LLC

Key Points

• Sterling Capital Management increased its Regeneron stake by 59.3% in the third quarter, bringing its holdings to 15,957 shares valued at approximately $12.1 million. Institutional investors collectively own 83.31% of the company.
• Regeneron reported quarterly revenue of $4.29 billion and EPS of $14.29, exceeding analyst estimates, while revenue rose 16.7% year over year. The company also pays a quarterly dividend of $0.94, yielding about 0.5%.
• Analyst sentiment remains favorable, with a consensus rating of Moderate Buy and an average price target of $846.28; recent targets range as high as $980. Shares recently traded near $805 after declining 1.7%.

Sterling Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,957 shares of the biopharmaceutical company's stock after purchasing an additional 5,943 shares during the quarter. Sterling Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $12,100,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. Legal & General Group Plc bought a new position in Regeneron Pharmaceuticals in the second quarter worth about $473,872,000. Bank of New York Mellon Corp purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $472,950,000. Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $323,249,000. Finally, Man Group plc bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $272,460,000. 83.31% of the stock is currently owned by institutional investors.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares of the company's stock, valued at approximately $10,291,252.17. This trade represents a 8.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock worth $6,506,845 over the last three months. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Down 1.7%

Shares of REGN traded down $14.07 during mid-day trading on Friday, reaching $805.02. The company had a trading volume of 527,731 shares, compared to its average volume of 705,231. Regeneron Pharmaceuticals, Inc. has a 52 week low of $575.93 and a 52 week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market capitalization of $82.88 billion, a price-to-earnings ratio of 19.90, a price-to-earnings-growth ratio of 1.38 and a beta of 0.16. The firm has a 50-day moving average price of $791.86 and a 200 day moving average price of $723.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the company posted $12.81 earnings per share. The company's revenue for the quarter was up 16.7% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.29%.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on REGN shares. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. TD Cowen upped their price target on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a "buy" rating in a research note on Wednesday. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an "overweight" rating in a research report on Tuesday, October 6th. Finally, Evercore boosted their target price on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an "outperform" rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $846.28.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.